Timothy S. Pardee, M.D., Ph.D.
Assistant Professor, Hematology & Oncology
cancer/oncogenesis, drugs/therapeutic agents pharm
Academic: 336-745-0424 | Department: 336-716-4464
Tawfik B, Sliesoraitis S, Lyerly S, Klepin HD, Lawrence J, Isom S, Ellis LR, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee T. Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML)
. Ann Hematol. 2014;93(1):47-55.
Pardee TS, Stadelman K, Jennings-Gee J, Caudell DL, Gmeiner WH. The poison oligonucleotide F10 is highly effective against acute lymphoblastic leukemia while sparing normal hematopoietic cells. Oncotarget. 2014;5(12):4170-4179.
Pardee TS, Lee K, Luddy J, Maturo C, Rodriguez R, Isom S, Miller LD, Stadelman KM, Levitan D, Hurd D, Ellis LR, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL. A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies
. Clin Cancer Res. 2014;20(20):5255-5264.
Manny JS, Pardee T, Pettenati M, Pang CS. Near-tetraploid/tetraploid acute myeloid leukemia: morphologic, cytogenetic, and prognostic features [abstract]. Mod Pathol. 2012;25(Suppl 2):354A.
Cook GJ, Caudell DL, Elford HL, Pardee T. The novel ribonucleotide reductase inhibitor didox is active against AML with limited toxicities [abstract]. Blood. 2012;120(21):Abstr 1513.
Cook GJ, Elford HL, Pardee T. Activity of the novel ribonucleotide reductase inhibitor didox on human and murine models of acute leukemia [abstract]. Blood. 2011;118(21):1553-1554.
Pardee T, Gomes E, Jennings-Gee J, Caudell DL, Gmeiner W. Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP10 results in high efficacy against AML and low toxicity [abstract]. Blood. 2011;118(21):1109-1110.
Pardee T, DeFord-Watts LM, Peronto E, Levitan DA, Hurd DD, Kridel S. Altered lipid and mitochondrial metabolism are viable targets in acute leukemia [abstract]. Blood. 2011;118(21):1546.
Pardee T. Over expression of MN1 accelerates leukemia onset and confers resistance to chemotherapy by suppression of p53 and Bim [abstract]. Blood. 2011;118(21):1070.
Chiou V, Tiegs J, Isom S, Pettenati MJ, Lyerly S, Ellis LR, Pardee T, Dmitriy B, Powell BL, Levitan DA. A single institution analysis of incidence of recurrent chromosomal abnormalities in adult ALL patients according to race, gender, and age [abstract]. Blood. 2011;118(21):4869.
Klepin HD, Tooze JA, Geiger AM, Kritchevsky S, Williamson J, Ellis LR, Levitan D, Pardee T, Isom S, Powell BL. Geriatric assessment predicts overall survival among older adults receiving induction chemotherapy for acute myelogenous leukemia [abstract]. Blood. 2010;116(21):653-654.
Pardee T, Mascenik T, Bolemon BH, Cook GJ. Over expression of MN1 confers resistance to chemotherapy in vitro and in vivo [abstract]. Blood. 2010;116(21):427.
Pardee T, Gomes E, Jennings-Gee J, Caudell DL, Gmeiner W. The novel fluoropyrimidine FdUMP is highly active against acute myeloid leukemia [abstract]. Blood. 2010;116(21):1353.
Pardee T, Zuber J, Lowe S. The FLT3 ITD accelerates an already established myeloid leukemia and alters chemotherapy response in vitro and in vivo in a p53 dependent manner [abstract]. Blood. 2009;114(22):685.
For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.
For a list of earlier publications, visit the Carpenter Library Publication Search.
Assistant Professor, Hematology & Oncology
Acute Leukemias, Chronic Leukemias, Myelodysplastic Syndromes, Hematologic Malignancies, Acute and Chronic Leukemia, Leukemia
The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.
*Dr. Pardee is one of the best staff I have ever met. Very knowledgeable.